Bumetanide
- Generic Name
- Bumetanide
- Brand Names
- Bumex, Burinex
- Drug Type
- Small Molecule
- Chemical Formula
- C17H20N2O5S
- CAS Number
- 28395-03-1
- Unique Ingredient Identifier
- 0Y2S3XUQ5H
- Background
Bumetanide is a sulfamyl diuretic.
- Indication
For the treatment of edema associated with congestive heart failure, hepatic and renal disease including the nephrotic syndrome.
- Associated Conditions
- Edema
Bumetanide vs. Furosemide in Cirrhosis
- First Posted Date
- 2025-04-23
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Stacy Johnson
- Target Recruit Count
- 500
- Registration Number
- NCT06941415
- Locations
- 🇺🇸
University of Utah Hospital, Salt Lake City, Utah, United States
Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Stefano Vicari
- Target Recruit Count
- 64
- Registration Number
- NCT06465823
- Locations
- 🇮🇹
Bambino Gesù Children's Hospital, Rome, Italy
Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts
- Conditions
- Heart Failure, Congestive
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Heart Center Research, LLC
- Target Recruit Count
- 80
- Registration Number
- NCT06218199
- Locations
- 🇺🇸
Heart Center Research, LLC, Huntsville, Alabama, United States
Bumetanide in Patients With Alzheimer's Disease
- First Posted Date
- 2023-09-25
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 40
- Registration Number
- NCT06052163
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
A Study of Ultra High Dose Diuretics to Treat Heart Failure
- Conditions
- Heart Failure; With Decompensation
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 20
- Registration Number
- NCT06036914
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment
- Conditions
- Acute Heart FailureDiuretics Drug Reactions
- Interventions
- Diagnostic Test: UNa measurement after intravenous loop diuretic bolusOther: Usual AHF careOther: Maintenance infusionOther: Intravenous hypertonic salineOther: Switch to oral diuretic therapy
- First Posted Date
- 2022-06-09
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Vrije Universiteit Brussel
- Target Recruit Count
- 107
- Registration Number
- NCT05411991
- Locations
- 🇧🇪
Jessa Hospital, Hasselt, Limburg, Belgium
🇧🇪University Hospital Brussels, Jette, Brussels, Belgium
Mechanisms of Diuretic Resistance in Heart Failure, Aim 1
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Yale University
- Target Recruit Count
- 75
- Registration Number
- NCT05323487
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
Role of Bumetanide in Treatment of Autism
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2021-02-23
- Lead Sponsor
- Sherief Abd-Elsalam
- Target Recruit Count
- 80
- Registration Number
- NCT04766177
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus
- Conditions
- HF - Heart FailureDiabetes Mellitus
- Interventions
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2022-05-10
- Lead Sponsor
- Northwestern University
- Registration Number
- NCT04697485
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial
- Conditions
- Renal Insufficiency, Chronic
- Interventions
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Hospital General de México Dr. Eduardo Liceaga
- Target Recruit Count
- 34
- Registration Number
- NCT03923933
- Locations
- 🇲🇽
Hospital General de Mexico, Mexico City, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.